Startup · $34m raised
Melbourne, VIC
Every investor coverage indicates participated in a round EpiMinder raised.
| Investor | Rounds | Invested |
|---|---|---|
| Bionics Institute | Bridge / extension · Series A | - |
| Cochlear | Bridge / extension · Series A | - |
| Seer Medical | Bridge / extension | - |
| St. Vincent's Hospital | Series A | - |
| University of Melbourne | Bridge / extension · Series A | - |
The transaction that ended EpiMinder's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| - | IPO | 1 Dec 2025 | $125m | Startup Daily, SmartCompany |
Companies EpiMinder acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Rohan Hoare | CEO | Startup Daily (Tue 2 Dec 2025), SmartCompany, Startup Daily (Tue 15 Mar 2022) |
| Professor Mark Cook | Chief Medical Officer · Founder | Startup Daily (Tue 2 Dec 2025), SmartCompany, Startup Daily (Wed 8 Oct 2025) |
Stories naming EpiMinder. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
An analysis of what happens to brain-implant trial participants once studies end, covering Australia's growing neurotech sector, EpiMinder's FDA approval, Synchron's funding, and recommendations from a convened panel of specialists.
Medical device firm Epiminder has joined the ASX, its shares dipping below issue price on debut, with the $125 million IPO proceeds earmarked for an American launch of its implantable epilepsy monitoring system next year.
Also Startup Daily
Ignition Lane's weekly roundup covers Linktree's unicorn raise, several Australian funding rounds, Tiger and Insight's new mega-funds, falling SaaS valuations, the ACCC's action against Meta, and new accelerator and product launches.
Epi-Minder has completed a $16 million bridge round with its existing shareholders to fund expanded clinical trials, product development and manufacturing of its long-term epilepsy monitoring device.